Get the Stockscreener App
8.77
3.52%
-0.32
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $8.77, with a volume of 19.13M.
It is down -3.52% in the last 24 hours and up +12.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.09
Open:
$9.015
24h Volume:
19.13M
Relative Volume:
1.34
Market Cap:
$10.26B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
-11.85
EPS:
-0.74
Net Cash Flow:
$1.89B
1W Performance:
+1.39%
1M Performance:
+12.58%
6M Performance:
-32.33%
1Y Performance:
-21.84%
1-Day Range:
$8.745
$9.315
1-Week Range:
$8.47
$9.575
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
8.77 | 10.26B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - marketscreener.com
VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on Behalf of Investors - GlobeNewswire
VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on ... - Bluefield Daily Telegraph
Viatris Inc. Class Action: Levi & Korsinsky Reminds Viatris Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025VTRS - Morningstar
Viatris Inc. Reports Q1 2025 Earnings and Outlook - TipRanks
Viatris, Inc. Earnings Call: Mixed Sentiments and Strategic Advances - TipRanks
Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year - insights.citeline.com
2025-05-08 | Viatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsVTRS | NDAQ:VTRS | Press Release - Stockhouse
Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock SoarsViatris (NASDAQ:VTRS) - Benzinga
Viatris: Q1 Earnings Snapshot - The Washington Post
Contact Levi & Korsinsky by June 3, 2025 Deadline to Join Class Action Against Viatris ... - Eagle-Tribune
Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive - Asianet Newsable
Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS) - Seeking Alpha
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains - TradingView
Viatris reports success in Phase 3 birth control patch study By Investing.com - Investing.com South Africa
Viatris’ new form of old pain drug scores in large trials - BioPharma Dive
Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost - GlobeNewswire
Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of ... - Bluefield Daily Telegraph
VIATRIS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc.VTRS - GlobeNewswire
Viatris Raises Profit Expectations Thanks To Chinese Demand - Finimize
Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8% - Yahoo Finance
Earnings call transcript: Viatris Q1 2025 earnings miss forecasts, stock rises - Investing.com
Viatris Inc SEC 10-Q Report - TradingView
Viatris Reports Q1 2025 Financial Results and Pipeline Progress - TipRanks
Viatris rises as Q1 beat comes with late-stage trial wins - MSN
Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China - marketscreener.com
Viatris stock gains after Q1 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris Q1 2025 slides: maintains guidance despite revenue decline, pipeline advances - Investing.com
Viatris stock gains on late-stage trial win (VTRS:NASDAQ) - Seeking Alpha
Viatris misses Q1 estimates, reaffirms 2025 outlook - Investing.com
Viatris reports success in Phase 3 birth control patch study - Investing.com
Viatris in charts: Generic sales drop 16% in Q1; revenue from Developed Markets falls 13% - Seeking Alpha
Viatris reports positive Phase 3 results for pain treatment MR-107A-02 - Investing.com
Viatris stock rises on late-stage trial win (VTRS:NASDAQ) - Seeking Alpha
Viatris Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025 - marketscreener.com
Viatris' pain drug meets main goals of two late-stage trials - marketscreener.com
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential - PR Newswire
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain - PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. LawsuitVTRS - PR Newswire
VIATRIS (VTRS) CLASS ACTION NOTICE: Berger Montague Encourages Investors With Substantial Losses to Contact the Firm By June 3, 2025 - TradingView
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Viatris, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - TradingView
Viatris Can Sell Copies of Heron Nausea Drugs in 2032 After Deal - Bloomberg Law News
VTRS SECURITIES UPDATE: Viatris Inc. Investors with Losses - GlobeNewswire
Viatris Q1 Earnings Preview: Analysts expect profit to decline by about 27% - Seeking Alpha
Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case - insights.citeline.com
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - marketscreener.com
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PR Newswire
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Viatris Announces Quarterly Dividend - PR Newswire
Do Wall Street Analysts Like Viatris Stock? - MSN
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):